These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 25260373)

  • 21. The efficacy of vortioxetine for the treatment of major depressive disorder.
    Dhir A; Sarvaiya J
    Expert Rev Neurother; 2014 Dec; 14(12):1349-63. PubMed ID: 25418918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Huang IC; Chang TS; Chen C; Sung JY
    Int J Neuropsychopharmacol; 2022 Dec; 25(12):969-978. PubMed ID: 35981958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
    Sanchez C; Asin KE; Artigas F
    Pharmacol Ther; 2015 Jan; 145():43-57. PubMed ID: 25016186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
    Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
    CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.
    Alvarez E; Perez V; Dragheim M; Loft H; Artigas F
    Int J Neuropsychopharmacol; 2012 Jun; 15(5):589-600. PubMed ID: 21767441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vortioxetine for the treatment of major depressive disorder.
    Tritschler L; Felice D; Colle R; Guilloux JP; Corruble E; Gardier AM; David DJ
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
    Inoue T; Nishimura A; Sasai K; Kitagawa T
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
    Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C
    Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
    McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
    J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vortioxetine for the treatment of major depression.
    Dhir A
    Drugs Today (Barc); 2013 Dec; 49(12):781-90. PubMed ID: 24524096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
    Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.
    Maneeton N; Maneeton B; Srisurapanont M; Martin SD
    BMC Psychiatry; 2012 Sep; 12():160. PubMed ID: 23017200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
    Adair M; Christensen MC; Florea I; Loft H; Fagiolini A
    J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
    Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G
    J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of vortioxetine.
    Schatzberg AF; Blier P; Culpepper L; Jain R; Papakostas GI; Thase ME
    J Clin Psychiatry; 2014 Dec; 75(12):1411-8. PubMed ID: 25551236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
    Baldwin DS; Chrones L; Florea I; Nielsen R; Nomikos GG; Palo W; Reines E
    J Psychopharmacol; 2016 Mar; 30(3):242-52. PubMed ID: 26864543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.